Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

 
• By Brenda Sandburg
  
WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.
FTC Requirements for the Celgene/Bristol-Myers Squibb Merger Reflect its Policy Shift on asset divestment.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Compliance

More from Pink Sheet